Kriya Therapeutics, Inc., Redwood CityCA and Research Triangle ParkNC-based fully integrated gene treatment company, advancing new technologies and therapeutics, raised $270m in Series C financing.
TheRound was led by Patient Square CapitalParticipation from Bluebird VenturesCAM Capital, Dexcel Pharma, Foresite CapitalJDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other unidentified investors.
TheCompany plans to use the funds for the advancement and scaling of its engineering, manufacturing, computational platforms, and pipeline.
LedBy Shankar Ramaswamy, M.D., Co-Founder Chief Executive Officer, Kriyahas created an ecosystem for the delivery of medicines and technologies inGene therapy with core business units in technology, manufacturing, R&D, and therapeutics. ByIts proprietary computational platform is used to make this possible inWith its own manufacturing infrastructure and rational design tools, the company is well-positioned to bring potential transformative gene therapies to many diseases.
InRecent months KriyaIt has reached several milestones in key areas of its business. The company significantly expanded its pipeline through its internal R&D efforts, as well as through acquisitions and partnerships with leading companies and academic institutions. In addition, KriyaOperated its scalable GMP manufacturing infrastructure in Research Triangle Park, North CarolinaSupport inProduction in-house from the beginning to the end of phase development ThisInfrastructure also facilitates the development of new technologies and processes that allow for consistent, large-scale manufacturing. Kriya has also scaled SIRVE™, its machine learning-enabled technology and cloud computing architecture, to support the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms.